Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.

Stable gene replacement by in vivo administration of lentiviral vectors (LVs) has therapeutic potential for metabolic disorders and other systemic diseases. We studied the expression of intracellular and secreted proteins by LVs in immunocompetent mice. Liver, spleen, and bone marrow cells were efficiently transduced. However, transgene expression, driven by a ubiquitous promoter, was limited by transgene-specific cellular and humoral immune responses, leading to the clearance of transduced cells. After green fluorescent protein (GFP) gene transfer, the liver showed infiltration of CD8(+) cytotoxic T cells, and GFP-specific CD8(+) T cells were isolated from the spleen. After human factor IX (hF.IX) gene transfer, anti-hF.IX antibodies were induced. These immune responses were not detected in mice injected with heat-inactivated or genome-lacking LVs or in GFP-transgenic mice, indicating that they were specifically triggered by transgene expression in vivo. Intriguingly, selective targeting of LV expression to hepatocytes limited the immune responses to the transgenes. By this approach, high levels of hF.IX, potentially in the therapeutic range, were reached and maintained long term in immunocompetent mice, without inducing antibody formation. These results prompt further studies in relevant animal models to explore the potential of in vivo LV administration for the gene therapy of hemophilias and other liver-based diseases.

[1]  M. Kay,et al.  A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. , 2003, Blood.

[2]  M. Chuah,et al.  Gene therapy for the hemophilias , 2003, Journal of thrombosis and haemostasis : JTH.

[3]  L. Naldini,et al.  Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells , 2003, Nature Medicine.

[4]  I. Miconnet,et al.  In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. , 2003, The Journal of clinical investigation.

[5]  I. Verma,et al.  Efficient production of human FVIII in hemophilic mice using lentiviral vectors. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  Yuqin Wang,et al.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. , 2003, The Journal of clinical investigation.

[7]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[8]  D. Collen,et al.  Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. , 2003, Blood.

[9]  S. Kochanek,et al.  Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. , 2003, Blood.

[10]  L. Ailles,et al.  Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. , 2002, Blood.

[11]  J. Neefjes,et al.  Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. , 2002, Molecular immunology.

[12]  B. Brown,et al.  Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. , 2002, Blood.

[13]  L. Naldini,et al.  Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. , 2002, Blood.

[14]  R. Herzog,et al.  Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. , 2002, Human gene therapy.

[15]  P. Romero,et al.  Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. , 2002, Human gene therapy.

[16]  M. Kay,et al.  A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. , 2002, Blood.

[17]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[18]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.

[19]  L. Naldini,et al.  Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. , 2002, Human gene therapy.

[20]  T. Dull,et al.  Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector , 2002, Nature Biotechnology.

[21]  D. Skelton,et al.  The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice , 2001, Gene Therapy.

[22]  M. Denaro,et al.  EGFP-transduced EL-4 cells from tumors in C57BL/6 mice , 2001, Gene Therapy.

[23]  A. Suhrbier,et al.  Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. , 2001, Vaccine.

[24]  R. Herzog,et al.  Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  R. Herzog,et al.  Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  K. High,et al.  Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice , 2001, Gene Therapy.

[27]  I. Verma,et al.  Transduction of liver cells by lentiviral vectors: analysis in living animals by fluorescence imaging. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  K. High.  Gene transfer as an approach to treating hemophilia. , 2001, Circulation research.

[29]  Luigi Naldini,et al.  Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.

[30]  Thomas N. Sato,et al.  Universal GFP reporter for the study of vascular development , 2000, Genesis.

[31]  M. Kay,et al.  Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. , 2000, Blood.

[32]  H. Ertl,et al.  Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[34]  I. Verma,et al.  Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  R. Zinkernagel,et al.  Immunological Memory , 2006 .

[36]  R. Morgan,et al.  Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. , 1999, Blood.

[37]  A. Beaudet,et al.  Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Sebastian Amigorena,et al.  Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells , 1999, Nature Cell Biology.

[39]  A. Beaudet,et al.  Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. , 1999, Human gene therapy.

[40]  D. Kohn,et al.  Immune response to green fluorescent protein: implications for gene therapy , 1999, Gene Therapy.

[41]  C. Caskey,et al.  Expanded-capacity adenoviral vectors--the helper-dependent vectors. , 1999, Molecular medicine today.

[42]  Katherine A. High,et al.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.

[43]  M. Kay,et al.  Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors , 1999, Nature Medicine.

[44]  James M. Wilson,et al.  Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers , 1998, Journal of Virology.

[45]  A. Gown,et al.  Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors , 1997, Nature Genetics.

[46]  M. Mehtali,et al.  Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression , 1997, Gene Therapy.

[47]  K. Pasi.  Gene therapy for haemophilia , 2001, Bailliere's clinical haematology.

[48]  M. Kay,et al.  Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. , 1995, Gene therapy.